Altamira Therapeutics' Peptide-Based Delivery Platform

Altamira Therapeutics, listed on Nasdaq as CYTO, published a study on using peptides derived from bee venom to enhance AAV cell transduction. The company is developing peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues, with flagship programs for siRNA using its OligoPhore™ / SemaPhore™ platforms. Altamira holds a 49% stake in its commercial-stage legacy asset Bentrio®, and is headquartered in Hamilton, Bermuda, with main operations in Basel, Switzerland.